PHARMARON(300759)

Search documents
10月22日生物经济(970038)指数跌0.81%,成份股普洛药业(000739)领跌
Sou Hu Cai Jing· 2025-10-22 10:24
资金流向方面,生物经济(970038)指数成份股当日主力资金净流出合计8.93亿元,游资资金净流入合 计1.43亿元,散户资金净流入合计7.5亿元。成份股资金流向详情见下表: | 代码 | 名称 | 主力净流入(元) | 主力净占比 游资净流入 (元) | | 游资净占比 散户净流入 (元) | | 散户净占比 | | --- | --- | --- | --- | --- | --- | --- | --- | | 300759 | 康龙化成 | 4659.18万 | 6.98% | -1163.58万 | -1.74% | -3495.60万 | -5.23% | | 301363 美好医疗 | | 2495.52万 | 8.30% | -785.07万 | -2.61% | -1710.45万 | -5.69% | | 300298 | 三诺生物 | 1733.36万 | 15.29% | -951.84万 | -8.40% | -781.53万 | -6.90% | | 300832 | 新产业 | 1543.14万 | 11.26% | -177.90万 | -1.30% | -1365.24万 | ...
10月20日生物经济(970038)指数涨0.08%,成份股我武生物(300357)领涨
Sou Hu Cai Jing· 2025-10-20 09:42
Core Points - The Bioeconomy Index (970038) closed at 2262.82 points, up 0.08%, with a trading volume of 19.253 billion yuan and a turnover rate of 1.3% [1] - Among the index constituents, 27 stocks rose, with Iwubio leading at a 10.07% increase, while 22 stocks fell, with Yifan Pharmaceutical leading the decline at 4.45% [1] Index Constituents Summary - The top ten constituents of the Bioeconomy Index include: - Mindray Medical (sz300760) with a weight of 13.81%, latest price at 223.47, down 0.90%, and a market cap of 270.944 billion yuan [1] - Changchun High-tech (sz000661) with a weight of 5.41%, latest price at 121.12, down 0.12%, and a market cap of 49.409 billion yuan [1] - Kanglong Chemical (sz300759) with a weight of 4.66%, latest price at 30.56, up 1.76%, and a market cap of 54.342 billion yuan [1] - Shizhu Aoshi (sz002252) with a weight of 4.52%, latest price at 6.67, up 0.15%, and a market cap of 44.275 billion yuan [1] - Biao Ge Shi Medicine (sz300347) with a weight of 4.23%, latest price at 54.08, up 0.95%, and a market cap of 46.564 billion yuan [1] - Shenzhen Technology (sz000021) with a weight of 4.08%, latest price at 27.24, down 0.58%, and a market cap of 42.693 billion yuan [1] - Muyuan Foods (sz002714) with a weight of 3.66%, latest price at 49.48, down 2.25%, and a market cap of 270.298 billion yuan [1] - Aimeike (sz300896) with a weight of 3.44%, latest price at 167.03, down 1.49%, and a market cap of 50.542 billion yuan [1] - Kailai Ying (sz002821) with a weight of 3.23%, latest price at 105.80, up 2.72%, and a market cap of 38.151 billion yuan [1] - Color Egg Therapy (sz002223) with a weight of 3.19%, latest price at 36.65, down 1.24%, and a market cap of 36.741 billion yuan [1] Capital Flow Summary - The Bioeconomy Index constituents experienced a net outflow of 599 million yuan from institutional investors and 215 million yuan from retail investors, while retail investors saw a net inflow of 814 million yuan [3] - Notable capital flows include: - Kanglong Chemical saw a net inflow of 74.766 million yuan from institutional investors, while retail investors experienced a net outflow of 49.703 million yuan [3] - Hualan Biological had a net inflow of 42.164 million yuan from institutional investors, with retail investors seeing a net outflow of 33.5328 million yuan [3] - Lepu Medical had a net inflow of 40.927 million yuan from institutional investors, while retail investors had a net outflow of 32.1814 million yuan [3] - Kailai Ying had a net inflow of 38.867 million yuan from institutional investors, with retail investors experiencing a net outflow of 16.4533 million yuan [3] - Iwubio had a net inflow of 23.192 million yuan from institutional investors, while retail investors saw a net outflow of 5.9208 million yuan [3]
医疗服务板块10月20日涨1.47%,创新医疗领涨,主力资金净流入7.58亿元
Zheng Xing Xing Ye Ri Bao· 2025-10-20 08:27
证券之星消息,10月20日医疗服务板块较上一交易日上涨1.47%,创新医疗领涨。当日上证指数报收于 3863.89,上涨0.63%。深证成指报收于12813.21,上涨0.98%。医疗服务板块个股涨跌见下表: | 代码 | 名称 | 主力净流入(元) | 主力净占比 游资净流入 (元) | | 游资净占比 散户净流入 (元) | | 散户净占比 | | --- | --- | --- | --- | --- | --- | --- | --- | | 002173 创新医疗 | | 5.45 Z | 27.90% | -3.29 Z | -16.82% | -2.16 Z | -11.08% | | 603259 药明康德 | | 2.67 乙 | 9.01% | -1.47 Z | -4.98% | -1.19 Z | -4.04% | | 300759 康龙化成 | | 7476.60万 | 11.46% | -2506.29万 | -3.84% | -4970.31万 | -7.62% | | 603127 | 昭衍新药 | 4801.69万 | 8.87% | -1669.09万 | -3.08% | ...
IVD出海行业专题
2025-10-19 15:58
Q&A 今年医药行业的整体表现如何?未来有哪些值得关注的板块和趋势? 今年以来,医药行业在 31 个一级行业中涨幅排名第 11 位,涨幅为 18.85%。 尽管上周表现较为一般,在 31 个一级行业中涨跌幅排名第 16 位,下跌了 2%,但值得注意的是,一些前期炒作的创新药小票在经历了长达 3 个月、超 过 40%的调整后开始反弹,这是一个积极信号。我们认为,医药行业经过这段 时间的调整后,创新药等板块有望随时启动。具体方向包括创新药及其产业链、 器械耗材出口、医疗设备招采持续改善、原料药价格触底及产能利用率提升, 以及部分中药企业的创新药布局。 创新药板块近期表现如何?未来投资机会如何? 创新药板块近期经历了一波整体调整,并受到中美贸易战风险影响进一步回调。 目前头部公司的调整幅度普遍在 20%至 30%,而中小市值公司许多已经调整 普洛药业原料药业务稳定增长,CDMO 业务快速发展,制剂与原料业务 回归长期成长轨道,有望开启新一轮成长周期。CDMO 研发人员扩充, API 项目储备充足,提供持续增量。 中国 IVD 产品注册量快速增长,国产替代加速。生化诊断、POCT 等领 域国产化率较高。中国 IVD ...
A股最大医疗ETF(512170)午后下探2%,场内溢价再起,“抄底资金”卷土重来?
Xin Lang Ji Jin· 2025-10-17 06:06
10月17日,医疗板块震荡走低。A股最大医疗ETF(512170)午后一度下探逾2%,实时成交超4.9亿 元。该基金最新规模257.30亿元,同类ETF中排名首位。 成份股方面,三博脑科跌逾6%居首,英科医疗、南微医学跌超4%,权重股药明康德跌超3%。 医疗ETF(512170)及其联接基金(联接A:162412,联接C:012323)被动跟踪中证医疗指数,该指 数前十大权重股分别为药明康德、迈瑞医疗、联影医疗、爱尔眼科、康龙化成、泰格医药、爱美客、新 产业、惠泰医疗、鱼跃医疗。 数据来源于沪深交易所、公开资料等。 风险提示:以上产品由基金管理人发行与管理,代销机构不承担产品的投资、兑付和风险管理责任。投 资人应当认真阅读《基金合同》、《招募说明书》、《基金产品资料概要》等基金法律文件,了解基金 的风险收益特征,选择与自身风险承受能力相适应的产品。基金过往业绩并不预示其未来表现,基金投 资须谨慎!销售机构(包括基金管理人直销机构和其他销售机构)根据相关法律法规对本基金进行风险 评价,投资者应及时关注基金管理人出具的适当性意见,各销售机构关于适当性的意见不必然一致,且 基金销售机构所出具的基金产品风险等级评价结 ...
康龙化成跌2.03%,成交额3.27亿元,主力资金净流出6218.17万元
Xin Lang Cai Jing· 2025-10-17 03:17
Core Viewpoint - Kanglong Chemical experienced a decline in stock price by 2.03% on October 17, 2023, with a current price of 30.45 CNY per share and a total market capitalization of 54.146 billion CNY [1] Group 1: Stock Performance - Year-to-date, Kanglong Chemical's stock price has increased by 19.41%, but it has seen a decline of 7.95% over the last five trading days and 6.22% over the last twenty days [1] - The stock's performance over the last sixty days shows an increase of 15.30% [1] Group 2: Financial Performance - For the first half of 2025, Kanglong Chemical reported a revenue of 6.441 billion CNY, representing a year-on-year growth of 14.93%, while the net profit attributable to shareholders decreased by 37.00% to 701 million CNY [2] - Since its A-share listing, the company has distributed a total of 1.794 billion CNY in dividends, with 1.007 billion CNY distributed over the last three years [3] Group 3: Shareholder Information - As of June 30, 2025, the number of shareholders for Kanglong Chemical increased by 10.12% to 87,900 [2] - The top ten circulating shareholders include notable funds such as China Europe Medical Health Mixed A and Hong Kong Central Clearing Limited, with varying changes in their holdings [3] Group 4: Business Overview - Kanglong Chemical, established on July 1, 2004, and listed on January 28, 2019, specializes in drug research, development, and production services [1] - The company's revenue composition includes laboratory services (60.43%), CMC services (21.58%), clinical research services (14.58%), and other services [1]
中国CDMO-2025 年第三季度前瞻:关注新订单与盈利韧性,以应对地缘政治不确定性-China Healthcare CDMOs_ 3Q25 preview_ Eyes on New Order and Earnings Resilience to Navigate Geopolitical Uncertainty
2025-10-17 01:46
Summary of Conference Call Notes on China Healthcare CDMOs Industry Overview - The focus is on the Contract Research Organization (CRO) and Contract Development and Manufacturing Organization (CDMO) sectors, particularly in China - Investor interest has increased due to strong performance in the second quarter of 2025, with a 27% growth compared to a 15% growth in the MXCN index [1][2] Key Points and Arguments 1. **Earnings Growth Expectations**: - Earnings growth for 3Q25 may moderate due to a high base effect, but sequential improvement is anticipated as projects progress and new capacity comes online [2][3] - Forecasted sales growth for major players: WuXi Apptec (+10%), Asymchem (+19%), and Pharmaron (+8%) compared to their 2Q25 growth rates of +20%, +28%, and +14% respectively [3] 2. **New Order Momentum**: - New order momentum is expected to remain resilient, supported by CMO projects and emerging modalities such as GLP-1/peptide capacity and Antibody-Drug Conjugates (ADCs) [2][8] - Anticipated improvements in 2026 as funding conditions recover following interest rate cuts [2] 3. **Policy and Geopolitical Factors**: - Ongoing policy uncertainty, particularly related to the US Biosecure Act, is likely to drive near-term share price volatility [2][11] - The Senate passed the FY26 NDAA with the US Biosecure Act included, which may impact companies identified as Chinese military entities operating in the US [11][12] 4. **Operational Excellence**: - Companies are focusing on operational excellence and technological advancements to secure client orders amidst geopolitical uncertainties [2][11] 5. **Capex and Investment**: - Major Chinese CDMO players are expected to maintain their FY25 capital expenditure budgets, continuing investments in peptide, ADCs, and global expansion [3][6] Additional Important Insights - **Backlog and Order Growth**: - WuXi Apptec's backlog growth in peptide and small molecule oral GLP-1 is a key focus area, along with Asymchem's order growth from peptides and ADCs [8] - The recovery in early-stage R&D remains mixed, with expectations of improvement in 2026 driven by funding recovery [8] - **Valuation and Price Targets**: - Target prices for companies such as Asymchem, Pharmaron, WuXi Apptec, WuXi Biologics, and WuXi XDC have been adjusted based on market conditions and company performance [20][23][24][25] - **Risks**: - Key risks include sensitivity to loss of key clients, pricing pressure, regulatory risks, and geopolitical tensions, particularly between the US and China [21][22][23][24][25] - **Expansion Plans**: - Chinese CDMOs are actively expanding operations overseas, with significant investments in the US and Europe [19] This summary encapsulates the critical insights from the conference call regarding the current state and future outlook of the China healthcare CDMO industry, highlighting both opportunities and risks.
回血!A股最大医疗ETF收复失地,港股通创新药ETF(520880)反弹超2%!资金高歌猛进,做多时刻到了?
Xin Lang Ji Jin· 2025-10-15 11:48
连续调整后,AH医药资产今日(10月15日)终于迎来反弹,创新药大口回血,CXO等相关产业链同步 上行。 A股方面,CXO反弹集体,九洲药业大涨6%,康龙化成、昭衍新药涨超4%,规模最大医疗ETF (512170)场内收涨1.34%收复上日失地,全天成交5.89亿元。 近日医疗ETF(512170)围绕60日均线震荡,巨量资金开始"抄底",近3日累计净买入超6.75亿元。今日 512170尚未收复60日线,或仍处于买盘区域。 A股创新药集体走强,华海药业领涨7.59%,兴齐眼药、三生国健、海思科齐涨逾5%,全市场唯一药 ETF(562050)重仓创新药,场内涨1.88%终结四连跌。 港股创新药涨势更甚,100%创新药研发标的——港股通创新药ETF(520880)午后稳步上行,场内收 涨2.12%,全天成交3.75亿元。 37只成份股35股收涨,绿叶制药领涨8.31%,亚盛医药-B、乐普生物-B、科伦博泰生物-B集体反弹逾 5%,百济神州、中国生物制药等核心权重股均收红。 资金动力来自何处?综合消息面和机构研判来看,创新药后续催化密集,或于四季度迎来第二波行情。 催化剂方面,2025年欧洲肿瘤内科学会(ESMO ...
10月15日生物经济(970038)指数涨1.32%,成份股博腾股份(300363)领涨
Sou Hu Cai Jing· 2025-10-15 09:53
Core Points - The Bioeconomy Index (970038) closed at 2319.65 points, up 1.32%, with a trading volume of 23.929 billion yuan and a turnover rate of 1.64% [1] - Among the index constituents, 39 stocks rose while 11 fell, with Boteng Co., Ltd. leading the gainers at 6.85% and Dabo Medical leading the decliners at 2.94% [1] Index Constituents Summary - The top ten constituents of the Bioeconomy Index include: - Mindray Medical (sz300760) with a weight of 13.81%, latest price at 230.50, and a market cap of 279.468 billion yuan [1] - Changchun High-tech (sz000661) with a weight of 5.41%, latest price at 127.16, and a market cap of 51.873 billion yuan [1] - Kanglong Chemical (sz300759) with a weight of 4.66%, latest price at 31.35, and a market cap of 55.746 billion yuan [1] - Other notable constituents include Taige Pharmaceutical, Deep Technology, and Muyuan Foods, each with varying weights and market caps [1] Capital Flow Analysis - The Bioeconomy Index constituents experienced a net inflow of 265 million yuan from institutional investors, while retail investors saw a net outflow of 72.932 million yuan [3] - Key stocks with significant capital flow include: - Mindray Medical with a net inflow of 79.5868 million yuan from institutional investors [3] - Xintai (002294) with a net inflow of 66.974 million yuan, but a net outflow of 87.6434 million yuan from retail investors [3] - Changchun High-tech also saw a net inflow of 66.9424 million yuan from institutional investors, with a notable outflow from retail investors [3]
康龙化成涨4.33%,成交额9.50亿元,近3日主力净流入-2.30亿
Xin Lang Cai Jing· 2025-10-15 07:55
Core Viewpoint - 康龙化成's stock increased by 4.33% on October 15, with a trading volume of 9.50 billion and a market capitalization of 557.46 billion [1] Company Overview - 康龙化成 (Beijing) New Drug Technology Co., Ltd. specializes in integrated drug research, development, and production services, covering the entire process from drug discovery to drug development [2][7] - The company's main revenue sources include laboratory services (60.43%), CMC (small molecule CDMO) services (21.58%), clinical research services (14.58%), and other services [7] Financial Performance - For the first half of 2025, 康龙化成 achieved a revenue of 64.41 billion, representing a year-on-year growth of 14.93%, while the net profit attributable to shareholders decreased by 37.00% to 7.01 billion [8] - The company has distributed a total of 17.94 billion in dividends since its A-share listing, with 10.07 billion distributed in the last three years [9] Market Position and Trends - 康龙化成 is a leader in the CRO (Contract Research Organization) sector, providing comprehensive CRMO solutions for drug discovery and development, focusing on small molecule drug research [2] - The company benefits from the depreciation of the RMB, with overseas revenue accounting for 84.95% of total revenue [3] Digital Transformation and Innovation - 康龙化成 has made significant progress in digital and intelligent construction within its clinical services, establishing a "Digital Innovation Technology Department" to enhance efficiency through AI and automation [3] - The integration of AI technology is expected to improve clinical service efficiency and reduce labor costs, although there may be risks related to management and technology integration [2][3]